Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Movers: GM, Ambac, Lehman Brothers, Chevron, Biogen, Elan, Cigna

Stocks in the news on Friday

From Standard & Poor's Equity ResearchGeneral Motors (GM) posts $11.21 second quarter adjusted loss per share, vs. $2.29 EPS from continuing operations a year ago, on 18% revenue drop. On reported basis, posts $27.33 loss, vs. $1.37 EPS. The auto maker cites significant losses in GM North America due to continuing U.S. industry volume declines, shifts in vehicle mix, long strike at American Axle (AXL), large lease-related charges; special charges associated with GM's ongoing restructuring actions; continued losses at GMAC Financial Services and updated estimates regarding recoveries and expectations of assumed benefit obligations in the Delphi bankruptcy.

Ambac Financial Group (ABK) settles one of its largest CDO exposures, AA Bespoke, in exchange for a final cash payment of $850 million to its sole counterparty. ABK says the benefit of this agreement is that it eliminates uncertainty with respect to future losses related to this transaction.

The NY Post says Lehman Brothers Holdings (LEH) is engaged in talks with prospective buyers about offloading some $30 billion in commercial mortgage assets and other hard-to-value securities that have dogged its balance sheet for months and ultimately resulted in the demotion of Chief Financial Officer Erin Callan and President Joseph Gregory. S&P maintains hold.

Chevron (CVX) posts $2.90, vs. $2.52, second quarter EPS on 48% revenue rise.

Sun Microsystems (JAVA) posts $0.35, vs. $0.50, fourth quarter non-GAAP EPS on 1.4% lower revenue. Sets additional $1 billion stock buyback.

Ingersoll-Rand (IR) posts $0.90, vs. $0.68, second quarter EPS from continuing operations on 38% revenue rise. Notes revenues and operating EPS of Trane (acquired June 5) for partial month of June are incl. in these results, along with one-time items related to acquisition costs. Posts $1.03 second quarter EPS from continuing operations (excluding items). Anticipates that combined cos will provide annual pre-tax cost, revenue synergies exceeding $300 million in 2010. Sees $1.05-$1.10 third quarter EPS from continuing operations (excluding items) on $4.4-$4.5 billion third quarter revenue, $3.80-$3.90 2008 EPS from continuing operatioms (excluding items).

On July 31, Biogen (BIIB) and Elan (ELN) notified relevant regulatory agencies of two confirmed cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with Tysabri in the commercial setting. Early, incorrectly reported Jefferies cut target on ELN. Jefferies cut its target on BIIB.

Cigna (CI) posts $1.08, vs. $0.98, second quarter adjusted operating EPS on 11% revenue rise. Sees $4.05-$4.25 2008 adjusted operating EPS.

Schering-Plough (SGP) announces that the FDA has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia. Says issues are primarily related to hypersensitivity/allergic reactions, not to the efficacy of sugammadex.

Cognizant Technology Solutions (CTSH) posts $0.39, vs. $0.30, second quarter non-GAAP EPS on 33% revenue rise. GAAP EPS was $0.35. Sees lower-than-expected third quarter revenue of at least $723 million, GAAP EPS of $0.37 ($0.41 non-GAAP). Forecasts 2008 revenue of at least $2.81 billion, GAAP EPS of at least $1.44 ($1.61 non-GAAP).

ValueClick (VCLK) posts $0.17, vs. $0.17, second quarter EPS as higher amortization of intangible assets offset 10% revenue rise. Sees $0.69-$0.71 2008 EPS. Street view for 2008 is currently $0.74. Says increased macroeconomic uncertainty makes revenue growth more challenging for the second half of the year.

Scientific Games (SGMS) posts $0.41, vs. $0.32, second quarter EPS (excluding Global Draw earn-out accrual, stock comp expenses) on 14% revenue rise. Street was looking for $0.33.

Scotts Miracle-Gro (SMG) posts $2.00, vs. $1.98, third quarter adjusted EPS on 7% sales rise. Continues to believe results for fiscal year 2008 will be at least $2.00 per share.

Synaptics (SYNA) posts $0.46, vs. $0.36, fourth quarter EPS on 35% revenue rise. Based on its backlog and current visibility, expects revenue in the first quarter to be $108-$114 million, suggesting revenue may grow 20%-30% in fiscal year 2009. Sets 3-for-2 stock dividend, and $80 million stock buyback.

Late yesterday, McAfee (MFE) posted $0.52, vs. $0.41, second quarter non-GAAP EPS on 26% revenue rise. Forecast third quarte revenue of $390-$400 million (vs. second quarter's $397 million), non-GAAP EPS of $0.46-$0.50. Sees $1.90-$2.00 2008 non-GAAP EPS. MFE also announced agreement to acquire Reconnex for $46 million.

KLA-Tencor (KLAC) posts better-than-expected $0.60, vs. $0.91, fourth quarter non-GAAP EPS on 18% revenue drop.

Weight Watchers International (WTW) posts $0.87, vs. $0.73, second quarter EPS (excluding charges) on 3.5% revenue rise. Narrows 2008 EPS guidance range to $2.85-$2.96 from $2.85-$3.00, excluding expense associated with the startup of its China joint venture and U.K. VAT charges resulting from a recent adverse ruling.

CBRL Group (CBRL) sets stock buyback of up to $65 million.

blog comments powered by Disqus